- Home
- GROY vs NGNE Comparison
GROY vs NGNE Comparison
Compare GROY & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GROY
- NGNE
- Stock Information
- Founded
- GROY 2020
- NGNE 2003
- Country
- GROY Canada
- NGNE United States
- Employees
- GROY 16
- NGNE N/A
- Industry
- GROY
- NGNE Biotechnology: Pharmaceutical Preparations
- Sector
- GROY
- NGNE Health Care
- Exchange
- GROY Nasdaq
- NGNE Nasdaq
- Market Cap
- GROY 618.0M
- NGNE 325.3M
- IPO Year
- GROY 2021
- NGNE N/A
- Fundamental
- Price
- GROY $3.62
- NGNE $18.48
- Analyst Decision
- GROY Strong Buy
- NGNE Strong Buy
- Analyst Count
- GROY 4
- NGNE 7
- Target Price
- GROY $4.58
- NGNE $41.86
- AVG Volume (30 Days)
- GROY 2.5M
- NGNE 110.1K
- Earning Date
- GROY 08-06-2025
- NGNE 08-11-2025
- Dividend Yield
- GROY N/A
- NGNE N/A
- EPS Growth
- GROY N/A
- NGNE N/A
- EPS
- GROY N/A
- NGNE N/A
- Revenue
- GROY $12,376,000.00
- NGNE N/A
- Revenue This Year
- GROY $82.74
- NGNE N/A
- Revenue Next Year
- GROY $51.73
- NGNE N/A
- P/E Ratio
- GROY N/A
- NGNE N/A
- Revenue Growth
- GROY 90.37
- NGNE N/A
- 52 Week Low
- GROY $1.16
- NGNE $6.88
- 52 Week High
- GROY $3.65
- NGNE $74.49
- Technical
- Relative Strength Index (RSI)
- GROY 65.91
- NGNE 35.93
- Support Level
- GROY $2.89
- NGNE $19.59
- Resistance Level
- GROY $3.37
- NGNE $20.46
- Average True Range (ATR)
- GROY 0.15
- NGNE 1.23
- MACD
- GROY 0.01
- NGNE -0.20
- Stochastic Oscillator
- GROY 85.59
- NGNE 13.37
About GROY Gold Royalty Corp.
Gold Royalty Corp is a precious metals-focused royalty and mineral streaming company. The company offers creative financing solutions to the metals and mining industry. The company's mission is to acquire royalties, streams and similar interests at varying stages of the mine life cycle to build a balanced portfolio offering near, medium and longer-term attractive returns for investors. It has its business as a single operating segment, being the investment in royalty and mineral stream interests. The company derives maximum revenue from Canada.
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.